Evidence mapPaperPMID 39430942Full record

ArticleChemical science2024

Visualization of membrane localization and the functional state of CB

M Wąsińska-Kałwa, A Omran, L Mach, L Scipioni, J Bouma, X Li, S Radetzki, Y Mostinski, M Schippers, T Gazzi and 15 more

Abstract read
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

M Wąsińska-KałwaLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
A OmranLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
L MachLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
L ScipioniDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila 67100 L'Aquila Italy mauro.maccarrone@univaq.it.ORCID https://orcid.org/0000-0003-4764-8296
J BoumaDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University 2333 CC Leiden The Netherlands.
X LiiHuman Institute, ShanghaiTech University Shanghai 201210 China.
S RadetzkiLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Y MostinskiLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
M SchippersRoche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd 4070 Basel Switzerland uwe.grether@roche.com.
T GazziLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
C van der HorstDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University 2333 CC Leiden The Netherlands.
B BrenneckeLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
A HanskeLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
Y KolomeetsLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
W GubaRoche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd 4070 Basel Switzerland uwe.grether@roche.com.
D SykesDivision of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham Nottingham NG7 2UH UK.
J P von KriesLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.
J BroichhagenLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.ORCID https://orcid.org/0000-0003-3084-6595
T HuaiHuman Institute, ShanghaiTech University Shanghai 201210 China.
D VeprintsevDivision of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham Nottingham NG7 2UH UK.
L H HeitmanDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University 2333 CC Leiden The Netherlands.
S OddiDepartment of Veterinary Medicine, University of Teramo Via R. Balzarini 1 64100 Teramo Italy soddi@unite.it.ORCID https://orcid.org/0000-0002-6217-698X
M MaccarroneDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila 67100 L'Aquila Italy mauro.maccarrone@univaq.it.ORCID https://orcid.org/0000-0002-3990-2963
U GretherRoche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd 4070 Basel Switzerland uwe.grether@roche.com.
M NazareLeibniz-Forschungsinstitut für Molekulare Pharmakologie FMP Campus Berlin-Buch 13125 Berlin Germany nazare@fmp-berlin.de.ORCID https://orcid.org/0000-0002-1602-2330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diversity of physiological roles of the endocannabinoid system has turned it into an attractive yet elusive therapeutic target. However, chemical probes with various functionalities could pave the way for a better understanding of the endocannabinoid system at the cellular level. Notably, inverse agonists of CB

Identifiers

PMID39430942
PMCPMC11485011

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.